JAZZ DEFA14A details CEO transition, board expansion, pay changes

Rhea-AI Filing Summary

Jazz Pharmaceuticals plc (JAZZ) has issued a DEFA14A supplement to its 2025 proxy materials outlining a planned CEO succession and related compensation adjustments.

• Leadership transition: President & COO Renee Gala will become President & Chief Executive Officer on 11 Aug 2025. Current CEO Bruce Cozadd will remain until that date, then serve in a transition role through 12 Sep 2025 before retiring while continuing as Board Chair.
• Board expansion: Board size increases from 12 to 13 seats; Ms. Gala will join as a Class I director with a term expiring in 2027.
• Compensation changes: Ms. Gala’s annual base salary rises to $1.2 million (from $0.9 million) and her target cash bonus to 110% of salary (from 80%), effective 11 Aug 2025.
• Equity awards: One-time promotion grant valued at ~$6.5 million (33% RSUs, 67% PSUs) in addition to her previously granted 2025 annual equity award of ~$6 million.
• Enhanced severance: Cash severance on involuntary termination without cause (outside a change-in-control period) increases to 150% of base salary plus up to 18 months of COBRA premiums (previously 100% salary and 12 months premiums).
• Voting impact: No changes to the proposals or proxy card for the 24 Jul 2025 AGM; shareholders are encouraged to review both the original proxy and this supplement.

Positive

• Orderly CEO succession from internal candidate supports strategic continuity.
• Board continuity retained through Cozadd’s ongoing role as Chairperson.

Negative

• Higher executive compensation (salary, bonus target, $6.5 M equity grant) increases shareholder cost.
• Severance benefits expanded, potentially raising future payout obligations.

Insights

Corporate Governance Analyst

TL;DR: Planned CEO hand-off to Renee Gala with higher pay; continuity preserved, costs rise; governance impact limited.

The filing formalises a well-telegraphed leadership transition. Naming the sitting President & COO as CEO signals continuity and should minimise execution risk. Adding Ms. Gala to the Board while keeping Mr. Cozadd as non-executive Chair maintains institutional knowledge but could raise modest board independence questions until roles settle. Compensation revisions—33% base-salary uptick, higher bonus leverage and a $6.5 million promotion grant—are sizeable but in line with large-cap biotech peers. Severance enhancements (150% salary, 18-month benefits) expand potential cost to shareholders yet remain below typical change-in-control multiples. Overall, the disclosure is routine proxy housekeeping with no direct effect on 2025 voting items or near-term financials; market impact should be neutral.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No. )

 

 

 

Filed by the Registrant ☒

 

Filed by a Party other than the Registrant ☐

Check the appropriate box:

 

☐ Preliminary Proxy Statement

 

☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

☐ Definitive Proxy Statement

 

☒ Definitive Additional Materials

 

☐ Soliciting Material Pursuant to Section 240.14a-12

JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

 

☒ No fee required.

 

☐ Fee paid previously with preliminary materials

 

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

 

 

SUPPLEMENT TO THE PROXY STATEMENT FOR THE

ANNUAL GENERAL MEETING OF SHAREHOLDERS

TO BE HELD ON JULY 24, 2025

 

 

Jazz Pharmaceuticals plc (the “Company,” “Jazz,” “we,” “us,” and “our”) is furnishing to you this supplement, dated July 10, 2025 (this “Supplement”), to supplement the 2025 Proxy Statement and Notice of Annual General Meeting of Shareholders, dated June 6, 2025 (the “Proxy Statement”), with respect to the solicitation of proxies by the Board of Directors of the Company for use at the 2025 Annual General Meeting of Shareholders to be held on Thursday, July 24, 2025 at 9:45 a.m., Local Time, at Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland.

The purpose of this Supplement is to provide information relating to the recently announced Chief Executive Officer transition and the changes to our Board of Directors and the compensation arrangements of certain of our named executive officers that will be made in connection therewith.

This Supplement should be reviewed together with the Proxy Statement. Except as described in this Supplement, the information provided in the Proxy Statement continues to apply and should be considered in voting your ordinary shares. To the extent that the information in this Supplement differs from or updates the information contained in the Proxy Statement, the information in this Supplement is more current and supersedes that information contained in the Proxy Statement.

CHIEF EXECUTIVE OFFICER AND BOARD CHANGES

On July 8, 2025, the Board of Directors (the “Board”) of Jazz Pharmaceuticals plc (the “Company”), appointed Renee Gala, the Company’s President and Chief Operating Officer, as the Company’s President & Chief Executive Officer, effective as of August 11, 2025. Concurrently therewith, the Board approved an increase in the number of directors constituting the full Board from 12 to 13 and, upon the recommendation of its nominating and corporate governance committee, appointed Ms. Gala to the Board, effective as of August 11, 2025, as a Class I director for a term expiring at the annual general meeting of shareholders to be held in 2027. Bruce Cozadd, Chairperson and Chief Executive Officer of the Company, will continue to serve in his Chief Executive Officer role until August 11, 2025, following which he will serve in a transition role through September 12, 2025, after which he will retire and will continue to serve as Chairperson of the Board, providing ongoing leadership and strategic guidance to the Company.

COMPENSATORY MATTERS

In connection with her appointment as President & Chief Executive Officer, the Board, upon the recommendation of its compensation and management development committee (the “Committee”), approved an increase of Ms. Gala’s annual base salary to $1,200,000, from $900,000, and an increase of her target bonus to 110% of her base salary, from 80%, in each case effective as of August 11, 2025. In connection with her appointment, Ms. Gala will also receive an additional one-time promotion equity grant with an approximate grant date value of $6,500,000. This promotion grant is incremental to her previous 2025 annual equity grant that had an approximate grant date value of $6,000,000. The promotion grant will consist of a mix composed of 33% of restricted stock units and 67% of performance stock units, in each case covering the Company’s ordinary shares. The restricted stock units will vest in equal annual installments over four years, and the performance stock units will vest based on the achievement of performance conditions previously established

by the Committee in the first quarter of 2025. The restricted stock unit and performance stock unit grants will, in each case, be subject to the terms and conditions of the Company’s 2011 Equity Incentive Plan and the award agreements thereunder. The Board also increased the amount of the severance payments and benefits to which Ms. Gala will be entitled in the event her employment terminates due to an involuntary termination without cause that does not occur upon or within 12 months following a change in control to a lump sum cash severance payment of 150% of her base salary in effect on the date of termination, from 100% of her base salary in effect on the date of termination, and to full payment of all the applicable COBRA premiums for any health, dental or vision plan sponsored by the Company for a period of up to 18 months following the involuntary termination, from 12 months following the involuntary termination.

VOTING MATTERS

This Supplement does not change the proposals to be acted upon at the Annual General Meeting of Shareholders, which proposals are described in the Proxy Statement, and there are no changes to the proxy card or voting instruction form previously mailed to shareholders.

YOU ARE URGED TO READ THE PROXY STATEMENT AND THIS SUPPLEMENT CAREFULLY IN DECIDING HOW TO VOTE. As a shareholder, your vote is very important and our Board of Directors encourages you to exercise your right to vote whether or not you plan to attend the Annual General Meeting of Shareholders.

*****

This Supplement, along with our previously furnished proxy materials, which include the Proxy Statement, our annual letter to shareholders, our 2024 Annual Report and our Irish financial statements for the fiscal year ended December 31, 2024 are available online at https://materials.proxyvote.com/G50871.

FAQ

When will Renee Gala become CEO of Jazz Pharmaceuticals (JAZZ)?

11 August 2025 is the effective date of her appointment as President & CEO.

How much will Renee Gala’s base salary increase under the new package?

Her annual salary will rise to $1.2 million from $900,000.

What is the value of the one-time promotion equity grant to the new CEO?

The Board approved a ~$6.5 million equity grant, 33% RSUs and 67% PSUs.

Does the DEFA14A change any proposals for the 24 July 2025 AGM?

No. All previously published proposals and proxy cards remain unchanged.

What severance multiple will apply to the new CEO if terminated without cause?

She would receive a lump-sum payment equal to 150% of base salary plus up to 18 months of COBRA premiums.

Will Bruce Cozadd remain involved after stepping down as CEO?

Yes, he will serve in a transition role until 12 Sep 2025 and then continue as Chairperson of the Board.